March 10th, 2022
SmithRx Announces $20 Million Series B Led by Venrock
San Francisco, California — 10 March 2022, 9:30 AM PT — SmithRx, a next-generation pharmacy benefits management company, today announced the closing of a $20 million series B financing round, following a year of record growth in which the company surpassed 1,100 employer clients. Venrock led the oversubscribed round and was joined by existing investors, including Founders Fund. The proceeds will support Smith’s plans for continued growth as it becomes the leader in next-generation pharmacy benefits management (PBM).
“Venrock’s deep experience in scaling health tech companies will be invaluable to Smith’s future growth and we are thrilled to partner with their team,” said Jake Frenz, Founder and CEO of SmithRx. “Smith continues to expand its foothold in the PBM sector as we put the power back in the hands of employers – our customers – who are the ones paying the pharmacy bills on behalf of their employees and members.”
The PBM industry has suffered from increasing inefficiency over the past decades, as incumbents have taken oversized margins while driving up drug costs for health plans, employers, and patients. SmithRx is leading the next-generation of pharmacy benefits with a tech-forward approach that provides full control and transparency to its clients. The company’s innovative, fully integrated cost savings programs proactively drive down drug costs.
The rapid adoption of the SmithRx solution is a testament to the pent-up demand for modern, customer-centric PBM services. Smith has built this solution by focusing on rebuilding PBM technology infrastructure from the ground up.
“The lack of visibility into pricing, combined with ever-increasing drug costs, demands a fresh and novel approach,” said Bryan Roberts, a partner at Venrock. “What the team at SmithRx has built over the last six years is delivering on its promise to save customers money, enabled by technology and empowered by transparency. We look forward to partnering with the SmithRx team on their company building journey.”
With this round, Roberts has joined the Board of Directors and Venrock partner Bob Kocher, MD is a Board Observer.
SmithRx reduces total drug costs and improves health outcomes with 100% pass-through pricing and the world’s most advanced PBM technology. With hundreds of broker and TPA partners, SmithRx has simplified pharmacy benefits with its leading-edge technology and easily-integrated cloud infrastructure, resulting in lower pharmacy costs for employers. Members benefit from SmithRx’s clinical programs and alternative sourcing, SmithRx Connect, to easily manage their prescription benefits and reduce overall drug spend. With offices in California and Utah, SmithRx was founded with the mission of offering a simple, completely transparent cloud-based alternative to traditional PBMs. For additional information on SmithRx, visit www.smithrx.com or send an email to email@example.com.
Originally established as the venture capital arm of the Rockefeller family in 1969, Venrock partners with entrepreneurs to build some of the world’s most disruptive, successful companies. With a primary focus on technology and healthcare, portfolio companies have included 10X Genomics, Apple Computer, AveXis, Check Point Software, CloudFlare, Dollar Shave Club, Gilead Sciences, Idec Pharma, Illumina, Intel, Millennium Pharma and Nest. For more information, please visit Venrock’s website at www.venrock.com and follow the firm on Twitter at @venrock.
Other Recent Posts
Introducing: SmithRx Low Cost Insulin Program
Diabetes is commonly one of the highest drug spend categories for employer groups. SmithRx is forging new pathways to make insulin more affordable. Starting July 1, 2023, biosimilar insulin products manufactured by Lilly will be preferred on the SmithRx formularies. In the SmithRx pass-through model, all the savings from filling biosimilar insulins are passed along… Continue reading Introducing: SmithRx Low Cost Insulin Program
Same drug, two different prices? Legacy PBMs play games with Humira biosimilars
On January 31, 2023, Amgen released Amjevita, the first biosimilar for AbbVie’s Humira. This ended AbbVie’s 20-year monopoly for a drug with a sticker price of $90,000/year, and finally introduced competition to bring down drug costs. While Amjevita is cheaper than Humira, its pricing structure is strange: it is offered at two different price points.… Continue reading Same drug, two different prices? Legacy PBMs play games with Humira biosimilars
SmithRx and Mark Cuban Cost Plus Pharmacy team up to reduce prescription drug costs
Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) has joined the SmithRx pharmacy network! SmithRx is one of the few pharmacy benefit cards that can be used at Cost Plus Drugs. Members can simply enter their SmithRx insurance information when creating an account at CostPlusDrugs.com. This expands access to more affordable prescription drugs for… Continue reading SmithRx and Mark Cuban Cost Plus Pharmacy team up to reduce prescription drug costs